Novartis tries again in US with everolimus for kidney transplantation
This article was originally published in Scrip
Executive Summary
The US FDA's cardiovascular and renal drugs advisory committee will meet on December 7th to consider Novartis' kinase inhibitor everolimus for prevention of kidney transplant rejection.